Skip to content
LATEST
US Politics

HHS Eases Enforcement on Six Unapproved Peptides, Overriding FDA Safety Standards

HHS has unilaterally authorized the sale of six unproven peptides by halting enforcement actions, overriding FDA safety warnings and raising concerns…

HHS Eases Enforcement on Six Unapproved Peptides, Overriding FDA Safety Standards

The Department of Health and Human Services (HHS) has issued an enforcement discretion policy allowing compounding pharmacies to produce and sell six specific peptides previously restricted by the Food and Drug Administration (FDA). The policy effectively bypasses formal regulatory review by declaring that federal authorities will not pursue enforcement actions against pharmacies manufacturing these substances.

The six peptides—BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500—lack clinical evidence of safety or efficacy. FDA scientists previously removed these substances from the approved compounding list due to documented safety concerns and insufficient data regarding human use.

This policy change follows the appointment of eight new members to the FDA advisory panel, several of whom maintain financial ties to the peptide industry. Critics argue that the move creates significant conflicts of interest and undermines established pharmaceutical safety protocols.

By facilitating the widespread availability of these substances, the policy may reduce incentives for formal clinical trials and increase the risk of adverse health outcomes. The decision marks a shift toward prioritizing market access over traditional regulatory oversight for unapproved medical products.

More stories

Latest news